Zoledronic acid (ZA) has been shown to inhibit prostate tumor growth in vitro and have beneficial effects in patients with advanced prostate cancer (CaP). The aim of this study was to determine whether ZA exhibits direct anti-tumor effects on CaP cells in vivo. To distinguish the effects of inhibition of osteolysis and direct antitumor activity of ZA in vivo, we compared the results of treatment with ZA and osteoprotegerin (Fc-OPG), which inhibits osteolysis, but without significant direct anti-tumor effects. In vitro Fc-OPG had no significant effects on C4-2 proliferation, whereas ZA decreased proliferation. However, both agents decreased tumor growth in bone. Moreover, both increased bone volume and prevented the overall decreases in BMD associated with growth of C4-2 cells in bone. Our study provides novel and significant observations that the in vivo effects of ZA are consistent with indirect effects mediated by osteoclasts.
Introduction
Advanced prostate cancer (CaP) is often accompanied by bone metastasis, which contributes significantly to the morbidity and mortality of the disease. The balance between osteoclastic bone resorption and osteoblastic bone formation is disrupted during tumor metastasis of many cancer types. In CaP, a large percentage of bone metastases have the radiographic appearance of osteoblastic lesions, but elevated markers of bone lysis are also present in the serum of CaP patients with bone metastasis. 1 Inhibitors of bone resorption such as bisphosphonates (BPs), osteoprotegerin (OPG), and metalloproteinase (MMP) inhibitors have been reported to decrease bone resorption associated with bone metastasis and decrease tumor burden in several animal models. [2] [3] [4] [5] [6] BPs are currently used to treat osteoporosis, reduce bone metabolic activity in Paget's disease, and control metastatic breast cancer and associated osteolytic bone lesions, as well as metastatic CaP. In a clinical study Diel et al 7 reported that clodronate, a first-generation BP, decreased numbers of both bone and soft tissue metastases in breast cancer patients, suggesting potential direct effects of BPs on metastases in addition to decreased bone lysis in vivo. Zoledronic acid (ZA) has also been reported to inhibit visceral metastases in a breast cancer model in vivo. 8 ZA is a new-generation BP and a very potent inhibitor of bone lysis. 9 The value and potential of ZA in treatment of patients with cancer-related bone disease were recently reviewed. 10 In addition to inhibition of osteolysis, several studies have shown that BPs, including ZA, exhibit direct anti-tumor effects in vitro. 4, 5, [11] [12] [13] We and others have also shown that ZA inhibits growth of osteoblastic CaP tumors in animal models. 4, 6 Unfortunately, no method has been found to distinguish the effects of ZA on osteoclasts and the accompanying indirect effect on tumor cells from the potential direct effects of these compounds on tumor cells in the bone environment in vivo. The effective concentrations of BPs in vitro were much higher than those used in vivo. Whether the known propensity of BPs to accumulate in bone could lead to sufficiently high concentrations in vivo to cause direct anti-tumor effects is unknown at present.
The aim of this study was to determine whether ZA exhibits direct anti-tumor effects on CaP cells in bone in vivo. To distinguish the effects of inhibition of osteolysis and direct anti-tumor activity of ZA in vivo, we compared the results of treatment with ZA and OPG, which inhibits osteolysis but without significant direct anti-tumor effects, 3, [14] [15] [16] [17] [18] [19] on C4-2 CaP bone metastases, with supportive studies in vitro.
Materials and methods

Cell proliferation
C4-2 cells, a subline of LNCaP cells, were purchased from Urocor, Inc. (Oklahoma City, OK, USA), and maintained under standard tissue culture conditions. For proliferation experiments, 2000 C4-2 cells were plated in RPMI 1640 medium without phenol red with 2% fetal bovine serum (FBS) per well in 96-well tissue culture plates. Cells were allowed to adhere overnight and Fc-OPG or ZA was added to the media (Fc-OPG: 0.001, 0.01, 0.1, 1, and 10 mM; ZA: 0.01, 0.1, 1, 10, and 100 mM). The recombinant Fc-OPG (a gift from Amgen, Inc., Thousands Oaks, CA, USA) contained the ligandbinding domain of human OPG fused to the Fc domain of human IgG, as described previously. 14, 20 ZA was supplied as the hydrated disodium salt (a gift from Novartis Pharma, Basel, Switzerland). Cells were treated for 4 days. Changes in proliferation were determined using the Quick Cell Proliferation Assay (BioVision Laboratories, Mountain View, CA, USA). This assay provides relative information on cell number based on the activity of mitochondrial dehydrogenases. Experiments were performed in quadruplicate and repeated 2-5 times. Student's t-test was used to determine the statistical significance of changes.
Animal studies
All procedures were performed in compliance with the University of Washington Institutional Animal Care and Use Committee and NIH guidelines. Male 4-6-week-old mice (Fox Chase SCID mice, Charles River, Wilmington, MA, USA) were used for the tibial injections of C4-2 cells. Animals were injected with B100 000 cells in 10 ml into the tibia as described previously. 21, 22 A total of 6 groups of 10 animals each were used: (1) Fc-OPG control group: Placebo PBS injection was administered three times a week. (2) Fc-OPG prevention group: Fc-OPG (150 mg/ injection) was administered 12 h prior to C4-2 injection and three times a week thereafter. (3) Fc-OPG treatment group: injections of Fc-OPG (150 mg per injection) started 3 weeks after C4-2 injection, when PSA serum levels were 43 ng/ml. (4) ZA control group: Placebo PBS injection was administered twice a week. (5) ZA prevention group: ZA (5 mg per injection) was administered 12 h prior to C4-2 injection and twice a week thereafter. (6) ZA treatment group: injections of ZA (5 mg/ injection) started 3 weeks after C4-2 injection, when PSA serum levels were 43 ng/ml. Blood samples were drawn from all animals weekly for determination of PSA serum levels (IMx Total PSA assay, a gift from Abbott Laboratories, Abbott Park, IL, USA). Animals were killed 8 weeks after C4-2 injection or when becoming compromised. The 8-week time frame was established in earlier experiments, based on the observation that at this point, the tumor is mostly localized in the tibiae. Prior to death animals were radiographed using a flat plate radiograph with a diagnostic mammography unit (35 kilovolts, 2.3 s, 20.7 mA/sec). Tibiae were harvested and processed for determination of bone mineral density (BMD) and bone histomorphometrical (BHM) analysis.
Bone densitometry
Both tibiae from all animals were used for BMD evaluation after excision from soft tissue. BMD was measured using dual-energy X-ray absorptiometry (DXA) on an Eclipse peripheral Dexa Scanner (Norland, Ft Atkinson, WI, USA) with company-provided research software. BMD was determined in a region of 25 mm Â 25 mm adjacent to the growth plate. The tibiae were scanned at 2 mm/s with a resolution of 0.1 mm Â 0.1 mm. Short-term BMD precision (% coefficient of variation) was less than 3%.
Bone histomorphometrical analysis
Undecalcified tibiae were embedded in methacrylate for BHM analysis, which was performed by Skeletech, Inc. (Bothell, WA, USA). Sections of 6 mm were stained by Goldner staining. Additional sections were stained for TRAP activity (marker for osteoclast) using a leukocyte acid phophatase kit (Sigma Chemical Company, St Louis, MO, USA). Analysis was performed in the area adjacent to the growth plate (0.525-1.225 mm below the growth plate, n ¼ 4-6/group) using the Osteomeasure bone analysis program (Osteometrics, Inc., Decatur, GA, USA). The percentages of bone volume and tumor volume in tissue volume (%BV/TV and %TuV/TV, respectively) were calculated. The trabecular thickness in mm (Tb.Th), trabecular number per mm (Tb.N), trabecular separation in mm (Tb.Sp), ratio of osteoblast surface to bone surface as a percentage (Ob.S/BS), and ratio of osteoclast surface to bone surface as a percentage (Oc.S/BS) were also determined.
Apoptosis
Five-mm sections of decalcified paraffin-embedded tibiae were used for analysis of effects of ZA and Fc-OPG on apoptosis. The TdT-FragEl DNA Fragmentation Detection kit (Oncogene, San Diego CA, USA) was used according to the manufacturer's directions. Percentages of positive nuclei were calculated in the longitudinal sections of the tibiae.
Statistical analysis
Significance of differences was examined using the Student's t-test (GraphPad Prism). OPG and zoledronic acid in CaP bone metastases JE Quinn et al are presented in Table 1 . Our data showed that there were significant correlations of %BV/TV with Tb.N., Tb.Sp., and Tb.Th. in C4-2 tibiae, but %BV/TV was not significantly correlated with any other parameters measured by BHM after administration of Fc-OPG and ZA. In our previous report about effects of ZA on prostate cells, we reported that ZA administration did not alter osteoblast number per bone surface, 4 while in our present study ZA administration significantly decreased the number of osteoblasts per bone surface. The differences in ObS/BS in response to ZA treatment may be due to different characteristics of the tumor cells used. C4-2 tumor cells cause mixed osteoblastic/osteolytic lesions with an increase in osteoblast number, but resulting in a net decrease in bone volume. LuCaP 23.1 tumor cells cause osteoblastic lesions with increases in osteoblast number and large increases in bone volume.
BHM analysis showed decreases in tumor volume (TuV/TV) following Fc-OPG and ZA administration (Figures 4a and b) . We did not detect significant differences in apoptotic cells between the treated groups (data not shown). In contrast to the BHM results, serum PSA levels were not significantly changed in animals receiving injections of Fc-OPG or ZA (Figures 4c and d,  respectively) . No correlation was seen between %TuV/ TV and serum levels of PSA. 
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C4-2--PREVENTION C4-2--TREATMENT a b Figure 3 Histology of C4-2 tibiae with or without Fc-OPG and ZA administration. C4-2 tibiae and contralateral non-tumored tibiae were embedded in methacrylate and stained using Goldner's procedure. Examples of tibiae treated with Fc-OPG (a) or ZA (b) are shown. Mineralized bone is green, bone marrow is purple, and tumor is pink or gray. Administration of Fc-OPG and ZA caused evident increases in mineralized bone in tumored and non-tumored tibiae vs untreated normal tibiae and tibiae with C4-2 metastases.
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Discussion
We have recently determined that ZA inhibits growth of CaP tumors in the murine bone environment. Inhibition of tumor growth was detected in lytic (PC-3) and blastic (LuCaP 23.1) models. 4 While a decrease in tumor volume in bone was detected after ZA treatment, we were unable to determine whether the effects observed were due to direct effects on the tumor or to indirect effects, which might include decreased release of growth factors from the bone matrix as a consequence of the known inhibitory effects of ZA on osteoclasts, phenotypic changes in osteoblasts, and restriction of the space for tumor growth within the bone marrow cavity. The existence of direct anti-tumor effects would suggest that treatment with ZA could be preferable to treatment with other compounds which also inhibit bone lysis but lack direct inhibitory effects on tumor cells. Treatment of subcutaneous tumors in a preclinical setting might be used to evaluate potential direct inhibitory effects of ZA on tumor cells. Failure to observe inhibition in such an experiment may indicate that there are no direct effects of ZA in vivo, and that the observed effects on tumors in bone are all related to inhibition of osteolysis. The caveat that attaches to this explanation is that the lack of inhibitory effects on the subcutaneous tumors may be due to low local concentrations (poor bioavailability) of ZA, at least in part because BPs have high affinity to bone and accumulate in bone. Conceivably ZA concentrations in bone could reach levels similar to those effective in vitro. There are data in the literature showing that alendronate reaches concentrations of 800-1000 mM at a resorptive site. 23 Unfortunately, no method has been found to distinguish the effects of ZA on osteoclasts and the accompanying indirect effect on tumor cells from the potential direct effects of these compounds on tumor cells in the bone environment in vivo.
In the current study, we have compared the inhibition mediated by ZA treatment with the effects of treatment by Fc-OPG. OPG is a secreted member of the tumor necrosis factor receptor family that plays a critical role in maintenance of the balance of bone remodeling.
14-17 Fc-OPG has been shown to inhibit osteolysis associated with bone metastases and decrease skeletal tumor burden. 3, 18 However, OPG has not been shown to have direct effects on tumor cells. 3, 18 In principle, similarities between the in vivo effects of Fc-OPG and ZA would indicate that any possible direct effects of ZA are of lesser importance, while significant differences in the observations would imply the opposite.
In our in vitro experiments ZA decreased the number of viable CaP cells, while Fc-OPG did not. In contrast, previously published in vivo data have demonstrated tumor inhibition by each compound, although no comparison has been reported. Herein we have shown that the degree of inhibition of tumor growth was closely similar with ZA and Fc-OPG. This is consistent with a model in which the in vivo effects of both compounds are mediated by indirect mechanisms involving inhibition of osteoclast activities. Further studies will be required to determine which of several potential indirect processes mentioned above may be involved. Moreover, it was recently reported that ZA exhibits direct effects on osteoblast, altering expression of RANKL and OPG in vitro. 24, 25 These effects might also affect bone remodeling and potentially alter tumor growth in vivo. For example, OPG has been shown to inhibit TRAIL-induced apoptosis of CaP cells in vitro. However, we have not observed decreased take rates of tumors treated with Fc-OPG, and Zhang et al 3 also reported on the absence of inhibitory effects of OPG on establishment or growth of subcuta- Animals with C4-2 cells in tibiae were subjected to administration of Fc-OPG or ZA 12 h prior to the cell injections (prevention groups) or 3 weeks after C4-2 cell injections (treatment groups). Fc-OPG was injected 3 times a week (150 mg per injection), and ZA was injected twice a week (5 mg per injection). Tumored and contralateral non-tumored tibiae were harvested and embedded in methacrylate. Bone histomorphometry analysis was performed on 4-6-mm sections using Goldner staining and TRAP staining in the area adjacent to the growth plate. Four to six samples per group were analyzed using an osteomeasure analysis system. Results are presented as mean7s.e.m. Significance of differences when compared to untreated C4-2 in bone was determined using Student's t-test.
neous CaP tumors. Nevertheless, the increased levels of OPG in patients with CaP bone metastases and under ZA treatment could diminish the effectiveness of TRAIL in tumor suppression if used in a clinical setting. The observation that Fc-OPG and ZA have similar effects in vivo does not constitute proof that no direct effects are involved in the action of ZA on CaP cells in bone. It is conceivable that the accumulation of ZA in bone may result in concentrations sufficient for direct anti-tumor effects. Instead the corollary of the present results is that indirect effects mediated by suppression of osteolytic activity are sufficient to give rise to significant inhibition of tumor growth, with or without direct effects.
Interestingly, despite decreases in tumor volumes after administration of ZA and Fc-OPG, serum PSA levels were not altered by the ZA and Fc-OPG treatments. PSA is a surrogate marker of CaP progression and response to therapy. Increasing levels of PSA in the serum of patients with recurrent CaP are indicative of tumor growth. PSA is also used to monitor the effectiveness of treatment of metastatic disease. In our studies, we observed discordance between the determinations of tumor volume by BHM and serum PSA levels. Two possibilities are proposed to explain this discrepancy. PSA may not reflect tumor changes in response of CaP bone metastases to Fc-OPG or ZA treatment, or, alternatively, it is possible that since BHM analysis performed in a limited two-dimensional section of tibiae is not representative of total tumor volume, while serum PSA levels represent total tumor volume. We have previously shown that administration of Fc-OPG or ZA decreased both tumor volume and serum PSA levels in LuCaP 23.1 osteoblastic CaP metastases. 4, 26 The differences between the results might be due to the different models of CaP metastases used in the two studies. LuCaP 23.1 is an androgen-sensitive CaP xenograft, while C4-2 cells are androgen insensitive. It is possible that these compounds have stronger effects on androgen-sensitive CaP tumors, or that PSA is not a good marker for monitoring the response to ZA or Fc-OPG of androgen-insensitive CaP tumors represented by C4-2 bone metastases. These results also indicate the need for caution in interpreting PSA serum levels as a surrogate marker for the effects of treatment in a clinical setting.
Conclusions
Despite the direct inhibitory effects of ZA on CaP cells in vitro, our characterization of the inhibition of tumor growth in vivo within the bone environment has yielded results that are consistent with a model in which the effects of ZA in this system are primarily attributable to indirect effects related to decreased bone lysis, paralleling the effects observed with OPG treatment. OPG and zoledronic acid in CaP bone metastases JE Quinn et al
